Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
May 14, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesEnkephalinase and endorphinase inhibitors as anti-craving compositions Method for eliciting anxiolysis Dietary supplement for children Treatment of cocaine addiction Use of cotinine in treating psychiatric disorders Methods for treating anxiety and panic Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent Patent #: 6117855 InventorsApplicationNo. 853392 filed on 05/14/2001US Classes:514/561Nitrogen other than as nitro or nitroso nonionically bondedExaminersPrimary: Jarvis, William R. A.Attorney, Agent or FirmForeign Patent References
International ClassA61K 031/195AbstractThe present invention relates to the use of gamma vinyl-GABA (GVG) to treat obsessive-compulsive disorder (OCD) and OCD-related disorders, and to reduce or eliminate behaviors associated with obsessive-compulsive disorder (OCD) and OCD-related disorders.Field of SearchNitrogen other than as nitro or nitroso nonionically bondedCarboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.) The nitrogen in R is an amino nitrogen attached indirectly to a ring by acyclic bonding Z radical contains nitrogen Chalcogen bonded directly to ring carbon of the hetero ring The additional ring is a hetero ring R is hydrogen or a lower saturated alkyl of less than seven carbons | |
